Therapeutic Targeting of PTPN13 in Idiopathic Pulmonary Fibrosis
Congressional District Code:
Biomedical Laboratory R&D
January 2017 -
FY 2021 Funding Amount:
Total Award Amount (all years):
View full abstract and other project information on NIH RePORTER Go To NIH RePORTER Excerpt:
DESCRIPTION (provided by applicant): Project summary Idiopathic pulmonary fibrosis (IPF) is a fatal fibrotic lung disease that compromises gas exchange in the alveoli. The median survival following diagnosis is approximately 3 years and there are few effective therapies. Although the specific causes of IPF are unknown, inhalation of dust, cigarette smoke and toxic chemicals are known risk factors for developing the disease, which most commonly develops in males as they enter their 60...